Digbi Health Unveils Integrated Hormone and GLP‑1 Therapy in Telehealth Platform

Hormone Therapy Meets Digital Care: What Patients Gain

Digbi Health announced today that its Precision Biology telehealth platform now offers clinical hormone replacement therapy alongside existing services for obesity, metabolic, gastrointestinal, and inflammatory conditions. The expansion, effective immediately, enables more than 300 employers and health plans that partner with Digbi to provide these new treatments under current contracts.

The company said the addition was driven by rising demand for personalized hormonal care and the proven benefits of GLP‑1 agents in managing weight and metabolic disorders. By bundling hormone therapy with its established virtual care model, Digbi aims to streamline patient journeys, reduce administrative burden, and improve outcomes through coordinated monitoring and data sharing.

Patients now receive a single, integrated platform that tracks hormone levels, medication adherence, and lifestyle metrics. Dr. Maya Patel, chief medical officer at Digbi, explained that the unified interface allows clinicians to adjust doses in real time and correlate hormonal changes with metabolic markers. „Patients no longer need separate appointments for endocrine and metabolic issues,” she said. „Everything is in one place, which cuts wait times and enhances compliance.”

How Does the Integration Work for Employers?

The platform uses secure, encrypted data exchange and AI‑driven analytics to flag potential complications early. Early adopters report a 15% reduction in follow‑up visits and a 12% improvement in patient-reported quality of life over a six‑month period.

Employers and health plans can now add hormone replacement therapy to their benefits portfolios without renegotiating contracts. The service is billed through existing arrangements, and the platform’s analytics provide employers with aggregate health metrics to inform wellness strategies. „We’re simplifying the process for employers,” said CEO Alex Ramirez. „They can offer comprehensive care while keeping costs transparent.”

The rollout includes training for primary care providers and endocrinologists on the platform’s workflow, ensuring that new patients receive consistent care across specialties. The company also plans to expand its library of clinical protocols to cover a broader range of hormonal disorders, such as thyroid dysfunction and menopause management.

Will This Shift Change the Landscape of Telehealth?

The integration of hormone therapy into a telehealth ecosystem signals a broader trend toward holistic, data‑driven care. Experts predict that such platforms could reduce the overall cost of chronic disease management by preventing complications that require expensive interventions. However, some caution that reimbursement models will need to evolve to fully capture the value of integrated care.

In the coming months, Digbi plans to launch pilot programs in select markets to evaluate long‑term outcomes and refine its algorithms. If successful, the model could become a benchmark for other telehealth providers seeking to offer comprehensive, personalized treatment plans.

Frequently Asked Questions

What conditions are covered by the new hormone therapy service? The platform currently supports testosterone replacement for men, estrogen and progesterone therapy for women, and thyroid hormone replacement. Future updates will include additional endocrine disorders.

How does billing work for employers already using Digbi? Employers can add hormone therapy to their existing contracts without new negotiations. Billing is integrated into the current payment structure, and detailed usage reports are provided.

Will patients need to visit a clinic for hormone therapy? Most hormone therapy can be initiated and monitored remotely. In‑person visits are reserved for initial assessments or complex cases that require blood draws or imaging.